Drug Profile


Alternative Names: LY 500307; SERBA-1

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Indiana University
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 23 Dec 2015 Phase-II development for Schizophrenia is ongoing in USA (NCT01874756)
  • 08 Jul 2011 Erteberel is still in phase II trials for Benign prostatic hyperplasia in USA, Australia, Canada, France, Germany, Greece, Italy and Russia
  • 21 Apr 2010 Phase-II clinical trials in Benign prostatic hyperplasia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top